Xuanzhu Biopharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Cash & Equivalents	8.56	135.25	142.89	1,125	625.5	93.34
Short-Term Investments	0.03	0.19	0.07	-	-	-
Trading Asset Securities	101.19	110.58	306.83	108.11	332.53	29.47
Cash & Short-Term Investments	109.79	246.02	449.8	1,233	958.02	122.81
Cash Growth	-91.10%	-45.30%	-63.53%	28.74%	680.10%	-
Accounts Receivable	4.02	0.19	-	-	-	-
Other Receivables	14.52	13.5	13.53	0.92	0.73	0.06
Receivables	18.54	13.69	13.53	0.95	5.81	0.08
Inventory	53.59	57.19	62.32	50.94	30.36	30.43
Other Current Assets	38.53	52.1	16.79	31.23	10.83	3.66
Total Current Assets	236.2	369	542.44	1,316	1,005	156.97
Property, Plant & Equipment	162.89	172.15	197.43	153.97	127.07	130.02
Other Intangible Assets	63.29	66.86	74.32	71.27	42.69	19.5
Long-Term Deferred Charges	566.35	543.7	459.48	270.12	217.22	297.93
Other Long-Term Assets	37.57	44.9	47.34	60.12	27.46	28.66
Total Assets	1,066	1,197	1,321	1,872	1,419	633.08
Accounts Payable	76.2	98.89	69.21	17.25	17.46	15.83
Accrued Expenses	10.38	16.59	20.24	35.61	21.56	24.04
Current Portion of Leases	0.85	0.83	5.15	-	-	-
Current Income Taxes Payable	2.44	-	-	0	0.03	-
Current Unearned Revenue	14.66	19.17	7.25	-	-	-
Other Current Liabilities	61.03	43.79	41.27	9	28.18	10.26
Total Current Liabilities	165.56	179.26	143.13	61.86	67.24	50.14
Long-Term Debt	-	-	-	-	-	8
Long-Term Leases	0.22	0.65	11.92	29.36	0.04	1.68
Long-Term Unearned Revenue	44.34	41.63	55.72	-	-	-
Other Long-Term Liabilities	10.38	18.37	-	-	-	-
Total Liabilities	220.5	239.91	210.76	91.22	67.28	59.82
Common Stock	450.61	450.61	450.61	450.61	1,413	1,024
Additional Paid-In Capital	1,890	1,890	1,890	2,041	664.58	111.99
Retained Earnings	-2,191	-2,081	-1,524	-711.3	-725.25	-562.8
Comprehensive Income & Other	696.58	696.58	293.69	-	0	0
Shareholders' Equity	845.81	956.71	1,110	1,781	1,352	573.27
Total Liabilities & Equity	1,066	1,197	1,321	1,872	1,419	633.08
Total Debt	1.07	1.48	17.07	29.36	0.04	9.68
Net Cash (Debt)	108.72	244.54	432.73	1,204	957.98	113.13
Net Cash Growth	-90.97%	-43.49%	-64.06%	25.68%	746.80%	-
Net Cash Per Share	0.24	0.54	0.96	3.05	-	-
Filing Date Shares Outstanding	517.95	450.61	450.61	450.61	-	-
Total Common Shares Outstanding	450.61	450.61	450.61	450.61	-	-
Working Capital	70.64	189.74	399.31	1,255	937.79	106.83
Book Value Per Share	1.88	2.12	2.46	3.95	-	-
Tangible Book Value	782.51	889.85	1,036	1,709	1,310	553.77
Tangible Book Value Per Share	1.74	1.97	2.30	3.79	-	-
Buildings	123.67	123.67	114.45	114.92	113.69	109.11
Machinery	126.81	126.8	126.47	85.5	77.8	69.79
Construction In Progress	1.81	1.79	1.64	-	-	2.65
Leasehold Improvements	3.66	3.66	3.66	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.